Iaso Biotherapeutics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Iaso biotherapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Iaso Biotherapeutics Today - Breaking & Trending Today

IASO Bio Announces CT103A Granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track (FT) Designations by the FDA

/PRNewswire/ IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative. ....

Equecabtagene Autoleucel , A Equecabtagene Autoleucel , China National Medical Products Administration , Drug Administration , Innovent Biologics Inc , Regenerative Medicine Advanced Therapy , Fast Track , New Drug Application , Breakthrough Therapy Designation , Orphan Drug Designation , Neuromyelitis Optica Spectrum Disorder , Innovent Biologics , Century Cures Act , Accelerated Approval , Priority Review , National Medical Products Administration , Iaso Biotherapeutics ,

IASO Bio Raises Nearly $75 Million in Series C1 Funding

/PRNewswire/ IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative. ....

Equecabtagene Autoleucel , Alan Fu , Umoja Biopharma , Jianhua Zhao , China National Medical Products Administration , Shanghai Guoxin Investment Development , Shanghai Waigaoqiao Free Trade Zone Group , Drug Administration , Approaches Commercialization , Shanghai Guoxin Investment , Efung Capital , New Drug Application , National Medical Products Administration , Investigational New Drug , Breakthrough Therapy Designation , Orphan Drug Designation , Neuromyelitis Optica Spectrum Disorder , Sana Biotechnology , Cabaletta Bio , Iaso Biotherapeutics ,

Iaso Bio Raises Nearly $75M in Series C1 Funding

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time! ....

Equecabtagene Autoleucel , Iaso Biotherapeutics , Iaso Bio , Shanghai Guoxin Investment Development , Shanghai Waigaoqiao Free Trade Zone Group , National Medical Products Administration , Drug Administration , Shanghai Guoxin Investment , Efung Capital , New Drug Application , Investigational New Drug , Breakthrough Therapy Designation , Orphan Drug Designation , Neuromyelitis Optica Spectrum Disorder ,

U.S. FDA Approves Clinical Trial Application for IASO Bio's BCMA CAR-T CT103A for Relapsed/Refractory Multiple Myeloma

/PRNewswire/ IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative. ....

United States , Wen Maxwell Wang , Research Conference , China National Medical Products Administration , European Hematology Association , Drug Administration , Investigational New Drug , National Medical Products Administration , Chief Executive Officer , New Drug Application , Breakthrough Therapy Designation , Orphan Drug Designation , Neuromyelitis Optica Spectrum Disorder , Iaso Biotherapeutics ,

World's First CAR-T for NMOSD Treatment, IASO Biotherapeutics' Equecabtagene Autoleucel, Receives IND Approval by NMPA

/PRNewswire/ IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative. ....

Neuromyelitis Optica , Equecabtagene Autoleucel , Wen Maxwell Wang , China National Medical Products Administration , Drug Evaluation , National Medical Products Administration , Neuromyelitis Optica Spectrum Disorder , Cytokine Release Syndrome , Expanded Disability Status Scale , Chief Executive Officer , Chief Medical Officer , Investigator Initiated Trial , New Drug Application , Breakthrough Therapy Designation , Orphan Drug Designation , Drug Designation , Iaso Biotherapeutics ,